Navigation Links
Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes
Date:10/8/2007

LONDON, October 8 /PRNewswire/ -- Innovation in the pharma industry is not at a standstill: it has changed direction. Where once small molecule research provided the mainstay of companies' profits, biological drugs are now making their presence felt. While the range of genomic sciences waits to make its impact, biologicals are providing the current focus for novel discovery. Yet biologicals do not behave like small molecules; the rules for their development are different and they are often little understood.

The 2007 update to the Scrip Report 'How Drugs are Developed' responds to these changes. First published four years ago, and revised in 2005, the Report aims to inform all those involved with pharmaceutical R&D how each of the necessary disciplines fit together to take a new medicine from discovery to market launch.

Sections of the Report that previously focused on small molecules have now been expanded to describe the corresponding processes for biologicals. To increase its value even further, the 2007 update features two brand new chapters. The first deals with project management: the fundamentals of managing multidisciplinary teams and the ways in which the role is changing to encompass external as well as internal interfaces. The second concerns the growing interest in translational research; the ways in which laboratory concepts can be converted into medical advances.

The 234-page update retains all the Report's original sections, giving readers a firm grounding in all the stages of drug development from drug target hunting, lead generation and optimisation through to preclinical research, clinical evaluation and post-marketing surveillance. It also gives a step-by-step account of the various stages of preparing for drug development and the processes involved in making regulatory submissions. The Report also includes over 60 figures all of which serve to aid the reader's understanding of the issues discussed.

When the first edition of the Report was published in 2003, the impact of sequencing the human genome was just being felt throughout the industry. Now, in 2007, it is apparent that while providing promise for the future, there will be no 'quick fix' for the industry and it must pursue an ever wider range of opportunities to achieve its goals. The result is a networked industry without historical parallel.

Scrip Reports publishes an extensive range of pharmaceutical therapeutic market reports, detailed analyses of the pharmaceutical market for specific geographic areas, in-depth profiles of companies operating in the industry, financial and statistical analyses, directories and other strategic reports on the healthcare sector.

Visit http://www.scripreports.com.

For further press details contact

Jenefer Trevena

Managing Editor

Scrip Publishing

Tel: +44-(0)20-7017-6989

Email: jenefer.trevena@informa.com.

To purchase How Drugs are Developed 2007, contact:

Andrew Maitland

Sales Manager

Tel: +44-(0)20-7017-6859

Email: andrew.maitland@informa.com

quote code JR20004P.


'/>"/>
SOURCE Scrip Reports
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Dane County mapping software updated, available to public
3. Lands End Debuts Updated Virtual Model
4. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
5. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
6. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
7. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
8. The development of a CXCR2 chemokine receptorbinding assay using the LEADseeker Multimodality Imaging System
9. The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System
10. The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System
11. The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the ... won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to ... Experience from US2020. , US2020’s mission is to change the trajectory of STEM ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, announces a ... in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):